Palisade Bio Inc (NASDAQ:PALI) — Market Cap & Net Worth
Market Cap & Net Worth: Palisade Bio Inc (PALI)
Palisade Bio Inc (NASDAQ:PALI) has a market capitalization of $294.52 Million ($294.52 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15003 globally and #3543 in its home market, demonstrating a -23.18% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Palisade Bio Inc's stock price $1.69 by its total outstanding shares 174270558 (174.27 Million). Also see Palisade Bio Inc balance sheet assets for a full breakdown of the balance sheet.
Palisade Bio Inc Market Cap History: 2015 to 2026
Palisade Bio Inc's market capitalization history from 2015 to 2026. Data shows change from $174.27 Trillion to $294.52 Million (-70.40% CAGR). Also see Palisade Bio Inc (PALI) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Palisade Bio Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.01% | #409 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1458 of 3165 |
Weight: Palisade Bio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Palisade Bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Palisade Bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check PALI share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
6169.18x
Palisade Bio Inc's market cap is 6169.18 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $55.75 Trillion | $16.25K | -$21.07 Million | 3431325714.14x | N/A |
| 2017 | $26.98 Trillion | $260.00K | -$15.67 Million | 103758009.15x | N/A |
| 2018 | $4.91 Trillion | $260.00K | -$4.92 Million | 18887577.13x | N/A |
| 2019 | $776.38 Billion | $15.39K | -$8.35 Million | 50433632.32x | N/A |
| 2020 | $690.11 Billion | $13.52K | -$10.32 Million | 51043743.32x | N/A |
| 2022 | $13.59 Billion | $250.00K | -$14.26 Million | 54372.41x | N/A |
| 2023 | $1.54 Billion | $250.00K | -$12.30 Million | 6169.18x | N/A |
Competitor Companies of PALI by Market Capitalization
Companies near Palisade Bio Inc in the global market cap rankings as of September 18, 2026. Review PALI tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Palisade Bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Palisade Bio Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Palisade Bio Inc's market cap moved from $174.27 Trillion to $ 294.52 Million, with a yearly change of -70.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $294.52 Million | -28.09% |
| 2025 | $409.54 Million | +42.42% |
| 2024 | $287.55 Million | -81.36% |
| 2023 | $1.54 Billion | -88.65% |
| 2022 | $13.59 Billion | -92.00% |
| 2021 | $169.91 Billion | -75.38% |
| 2020 | $690.11 Billion | -11.11% |
| 2019 | $776.38 Billion | -84.19% |
| 2018 | $4.91 Trillion | -81.80% |
| 2017 | $26.98 Trillion | -51.61% |
| 2016 | $55.75 Trillion | -68.01% |
| 2015 | $174.27 Trillion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Palisade Bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $294.52 Million USD |
| MoneyControl | $294.52 Million USD |
| MarketWatch | $294.52 Million USD |
| marketcap.company | $294.52 Million USD |
| Reuters | $294.52 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Palisade Bio Inc
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibroste… Read more